The initiation of coverage by Scotiabank with a Sector Perform rating suggests a neutral stance on Apellis Pharmaceuticals. The price target of $35 provides a specific valuation expectation, which may influence investor sentiment. However, the neutral rating implies no significant short-term price movement is expected.